COVID-19 Impact on Global Sympathomimetic Agents Market Size, Status and Forecast 2020-2026

July 2020 | 151 pages | ID: C5859E6D4342EN
QYResearch

Abstracts

This report focuses on the global Sympathomimetic Agents status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Sympathomimetic Agents development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study

• Pfizer
• Sanofi
• Novartis
• Sterimax
• Bedford Pharmaceuticals
• Teva
• Amneal Biosciences
• Baxter Laboratories
• Hikma Pharmaceuticals
• Amphastar Pharmaceuticals
• Marathon Pharmaceuticals
• Bausch Health Companies
• Sterling-Winthrop
• Cipla USA
• Nexus Pharmaceuticals
• Mylan
• Impax
• ALK Abello
• Lincoln Medical
• Amphastar
• Emerade
• Grand Pharma
• Harvest Pharmaceuticals
• Merit Pharmaceutical
• Tianjin Jinyao Group

Market segment by Type, the product can be split into

• Dobutamine
• Dopamine
• Ephedrine
• Epinephrine
• Isoproterenol
• Mephentermine
• Metaraminol
• Methoxamine
• Norepinephrine
• Phenylephrine

Market segment by Application, split into

• Anaphylaxis
• Cardiac Arrest
• Others

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

The study objectives of this report are:

• To analyze global Sympathomimetic Agents status, future forecast, growth opportunity, key market and key players.
• To present the Sympathomimetic Agents development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Sympathomimetic Agents are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Sympathomimetic Agents Revenue
1.4 Market Analysis by Type
  1.4.1 Global Sympathomimetic Agents Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 Dobutamine
  1.4.3 Dopamine
  1.4.4 Ephedrine
  1.4.5 Epinephrine
  1.4.6 Isoproterenol
  1.4.7 Mephentermine
  1.4.8 Metaraminol
  1.4.9 Methoxamine
  1.4.10 Norepinephrine
  1.4.11 Phenylephrine
1.5 Market by Application
  1.5.1 Global Sympathomimetic Agents Market Share by Application: 2020 VS 2026
  1.5.2 Anaphylaxis
  1.5.3 Cardiac Arrest
  1.5.4 Others
1.6 Coronavirus Disease 2019 (Covid-19): Sympathomimetic Agents Industry Impact
  1.6.1 How the Covid-19 is Affecting the Sympathomimetic Agents Industry
    1.6.1.1 Sympathomimetic Agents Business Impact Assessment - Covid-19
    1.6.1.2 Supply Chain Challenges
    1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  1.6.2 Market Trends and Sympathomimetic Agents Potential Opportunities in the COVID-19 Landscape
  1.6.3 Measures / Proposal against Covid-19
    1.6.3.1 Government Measures to Combat Covid-19 Impact
    1.6.3.2 Proposal for Sympathomimetic Agents Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Sympathomimetic Agents Market Perspective (2015-2026)
2.2 Sympathomimetic Agents Growth Trends by Regions
  2.2.1 Sympathomimetic Agents Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Sympathomimetic Agents Historic Market Share by Regions (2015-2020)
  2.2.3 Sympathomimetic Agents Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Sympathomimetic Agents Market Growth Strategy
  2.3.6 Primary Interviews with Key Sympathomimetic Agents Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Sympathomimetic Agents Players by Market Size
  3.1.1 Global Top Sympathomimetic Agents Players by Revenue (2015-2020)
  3.1.2 Global Sympathomimetic Agents Revenue Market Share by Players (2015-2020)
  3.1.3 Global Sympathomimetic Agents Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Sympathomimetic Agents Market Concentration Ratio
  3.2.1 Global Sympathomimetic Agents Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Sympathomimetic Agents Revenue in 2019
3.3 Sympathomimetic Agents Key Players Head office and Area Served
3.4 Key Players Sympathomimetic Agents Product Solution and Service
3.5 Date of Enter into Sympathomimetic Agents Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Sympathomimetic Agents Historic Market Size by Type (2015-2020)
4.2 Global Sympathomimetic Agents Forecasted Market Size by Type (2021-2026)

5 SYMPATHOMIMETIC AGENTS BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Sympathomimetic Agents Market Size by Application (2015-2020)
5.2 Global Sympathomimetic Agents Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Sympathomimetic Agents Market Size (2015-2020)
6.2 Sympathomimetic Agents Key Players in North America (2019-2020)
6.3 North America Sympathomimetic Agents Market Size by Type (2015-2020)
6.4 North America Sympathomimetic Agents Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Sympathomimetic Agents Market Size (2015-2020)
7.2 Sympathomimetic Agents Key Players in Europe (2019-2020)
7.3 Europe Sympathomimetic Agents Market Size by Type (2015-2020)
7.4 Europe Sympathomimetic Agents Market Size by Application (2015-2020)

8 CHINA

8.1 China Sympathomimetic Agents Market Size (2015-2020)
8.2 Sympathomimetic Agents Key Players in China (2019-2020)
8.3 China Sympathomimetic Agents Market Size by Type (2015-2020)
8.4 China Sympathomimetic Agents Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Sympathomimetic Agents Market Size (2015-2020)
9.2 Sympathomimetic Agents Key Players in Japan (2019-2020)
9.3 Japan Sympathomimetic Agents Market Size by Type (2015-2020)
9.4 Japan Sympathomimetic Agents Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Sympathomimetic Agents Market Size (2015-2020)
10.2 Sympathomimetic Agents Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Sympathomimetic Agents Market Size by Type (2015-2020)
10.4 Southeast Asia Sympathomimetic Agents Market Size by Application (2015-2020)

11 INDIA

11.1 India Sympathomimetic Agents Market Size (2015-2020)
11.2 Sympathomimetic Agents Key Players in India (2019-2020)
11.3 India Sympathomimetic Agents Market Size by Type (2015-2020)
11.4 India Sympathomimetic Agents Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Sympathomimetic Agents Market Size (2015-2020)
12.2 Sympathomimetic Agents Key Players in Central & South America (2019-2020)
12.3 Central & South America Sympathomimetic Agents Market Size by Type (2015-2020)
12.4 Central & South America Sympathomimetic Agents Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Pfizer
  13.1.1 Pfizer Company Details
  13.1.2 Pfizer Business Overview and Its Total Revenue
  13.1.3 Pfizer Sympathomimetic Agents Introduction
  13.1.4 Pfizer Revenue in Sympathomimetic Agents Business (2015-2020))
  13.1.5 Pfizer Recent Development
13.2 Sanofi
  13.2.1 Sanofi Company Details
  13.2.2 Sanofi Business Overview and Its Total Revenue
  13.2.3 Sanofi Sympathomimetic Agents Introduction
  13.2.4 Sanofi Revenue in Sympathomimetic Agents Business (2015-2020)
  13.2.5 Sanofi Recent Development
13.3 Novartis
  13.3.1 Novartis Company Details
  13.3.2 Novartis Business Overview and Its Total Revenue
  13.3.3 Novartis Sympathomimetic Agents Introduction
  13.3.4 Novartis Revenue in Sympathomimetic Agents Business (2015-2020)
  13.3.5 Novartis Recent Development
13.4 Sterimax
  13.4.1 Sterimax Company Details
  13.4.2 Sterimax Business Overview and Its Total Revenue
  13.4.3 Sterimax Sympathomimetic Agents Introduction
  13.4.4 Sterimax Revenue in Sympathomimetic Agents Business (2015-2020)
  13.4.5 Sterimax Recent Development
13.5 Bedford Pharmaceuticals
  13.5.1 Bedford Pharmaceuticals Company Details
  13.5.2 Bedford Pharmaceuticals Business Overview and Its Total Revenue
  13.5.3 Bedford Pharmaceuticals Sympathomimetic Agents Introduction
  13.5.4 Bedford Pharmaceuticals Revenue in Sympathomimetic Agents Business (2015-2020)
  13.5.5 Bedford Pharmaceuticals Recent Development
13.6 Teva
  13.6.1 Teva Company Details
  13.6.2 Teva Business Overview and Its Total Revenue
  13.6.3 Teva Sympathomimetic Agents Introduction
  13.6.4 Teva Revenue in Sympathomimetic Agents Business (2015-2020)
  13.6.5 Teva Recent Development
13.7 Amneal Biosciences
  13.7.1 Amneal Biosciences Company Details
  13.7.2 Amneal Biosciences Business Overview and Its Total Revenue
  13.7.3 Amneal Biosciences Sympathomimetic Agents Introduction
  13.7.4 Amneal Biosciences Revenue in Sympathomimetic Agents Business (2015-2020)
  13.7.5 Amneal Biosciences Recent Development
13.8 Baxter Laboratories
  13.8.1 Baxter Laboratories Company Details
  13.8.2 Baxter Laboratories Business Overview and Its Total Revenue
  13.8.3 Baxter Laboratories Sympathomimetic Agents Introduction
  13.8.4 Baxter Laboratories Revenue in Sympathomimetic Agents Business (2015-2020)
  13.8.5 Baxter Laboratories Recent Development
13.9 Hikma Pharmaceuticals
  13.9.1 Hikma Pharmaceuticals Company Details
  13.9.2 Hikma Pharmaceuticals Business Overview and Its Total Revenue
  13.9.3 Hikma Pharmaceuticals Sympathomimetic Agents Introduction
  13.9.4 Hikma Pharmaceuticals Revenue in Sympathomimetic Agents Business (2015-2020)
  13.9.5 Hikma Pharmaceuticals Recent Development
13.10 Amphastar Pharmaceuticals
  13.10.1 Amphastar Pharmaceuticals Company Details
  13.10.2 Amphastar Pharmaceuticals Business Overview and Its Total Revenue
  13.10.3 Amphastar Pharmaceuticals Sympathomimetic Agents Introduction
  13.10.4 Amphastar Pharmaceuticals Revenue in Sympathomimetic Agents Business (2015-2020)
  13.10.5 Amphastar Pharmaceuticals Recent Development
13.11 Marathon Pharmaceuticals
  10.11.1 Marathon Pharmaceuticals Company Details
  10.11.2 Marathon Pharmaceuticals Business Overview and Its Total Revenue
  10.11.3 Marathon Pharmaceuticals Sympathomimetic Agents Introduction
  10.11.4 Marathon Pharmaceuticals Revenue in Sympathomimetic Agents Business (2015-2020)
  10.11.5 Marathon Pharmaceuticals Recent Development
13.12 Bausch Health Companies
  10.12.1 Bausch Health Companies Company Details
  10.12.2 Bausch Health Companies Business Overview and Its Total Revenue
  10.12.3 Bausch Health Companies Sympathomimetic Agents Introduction
  10.12.4 Bausch Health Companies Revenue in Sympathomimetic Agents Business (2015-2020)
  10.12.5 Bausch Health Companies Recent Development
13.13 Sterling-Winthrop
  10.13.1 Sterling-Winthrop Company Details
  10.13.2 Sterling-Winthrop Business Overview and Its Total Revenue
  10.13.3 Sterling-Winthrop Sympathomimetic Agents Introduction
  10.13.4 Sterling-Winthrop Revenue in Sympathomimetic Agents Business (2015-2020)
  10.13.5 Sterling-Winthrop Recent Development
13.14 Cipla USA
  10.14.1 Cipla USA Company Details
  10.14.2 Cipla USA Business Overview and Its Total Revenue
  10.14.3 Cipla USA Sympathomimetic Agents Introduction
  10.14.4 Cipla USA Revenue in Sympathomimetic Agents Business (2015-2020)
  10.14.5 Cipla USA Recent Development
13.15 Nexus Pharmaceuticals
  10.15.1 Nexus Pharmaceuticals Company Details
  10.15.2 Nexus Pharmaceuticals Business Overview and Its Total Revenue
  10.15.3 Nexus Pharmaceuticals Sympathomimetic Agents Introduction
  10.15.4 Nexus Pharmaceuticals Revenue in Sympathomimetic Agents Business (2015-2020)
  10.15.5 Nexus Pharmaceuticals Recent Development
13.16 Mylan
  10.16.1 Mylan Company Details
  10.16.2 Mylan Business Overview and Its Total Revenue
  10.16.3 Mylan Sympathomimetic Agents Introduction
  10.16.4 Mylan Revenue in Sympathomimetic Agents Business (2015-2020)
  10.16.5 Mylan Recent Development
13.17 Impax
  10.17.1 Impax Company Details
  10.17.2 Impax Business Overview and Its Total Revenue
  10.17.3 Impax Sympathomimetic Agents Introduction
  10.17.4 Impax Revenue in Sympathomimetic Agents Business (2015-2020)
  10.17.5 Impax Recent Development
13.18 ALK Abello
  10.18.1 ALK Abello Company Details
  10.18.2 ALK Abello Business Overview and Its Total Revenue
  10.18.3 ALK Abello Sympathomimetic Agents Introduction
  10.18.4 ALK Abello Revenue in Sympathomimetic Agents Business (2015-2020)
  10.18.5 ALK Abello Recent Development
13.19 Lincoln Medical
  10.19.1 Lincoln Medical Company Details
  10.19.2 Lincoln Medical Business Overview and Its Total Revenue
  10.19.3 Lincoln Medical Sympathomimetic Agents Introduction
  10.19.4 Lincoln Medical Revenue in Sympathomimetic Agents Business (2015-2020)
  10.19.5 Lincoln Medical Recent Development
13.20 Amphastar
  10.20.1 Amphastar Company Details
  10.20.2 Amphastar Business Overview and Its Total Revenue
  10.20.3 Amphastar Sympathomimetic Agents Introduction
  10.20.4 Amphastar Revenue in Sympathomimetic Agents Business (2015-2020)
  10.20.5 Amphastar Recent Development
13.21 Emerade
  10.21.1 Emerade Company Details
  10.21.2 Emerade Business Overview and Its Total Revenue
  10.21.3 Emerade Sympathomimetic Agents Introduction
  10.21.4 Emerade Revenue in Sympathomimetic Agents Business (2015-2020)
  10.21.5 Emerade Recent Development
13.22 Grand Pharma
  10.22.1 Grand Pharma Company Details
  10.22.2 Grand Pharma Business Overview and Its Total Revenue
  10.22.3 Grand Pharma Sympathomimetic Agents Introduction
  10.22.4 Grand Pharma Revenue in Sympathomimetic Agents Business (2015-2020)
  10.22.5 Grand Pharma Recent Development
13.23 Harvest Pharmaceuticals
  10.23.1 Harvest Pharmaceuticals Company Details
  10.23.2 Harvest Pharmaceuticals Business Overview and Its Total Revenue
  10.23.3 Harvest Pharmaceuticals Sympathomimetic Agents Introduction
  10.23.4 Harvest Pharmaceuticals Revenue in Sympathomimetic Agents Business (2015-2020)
  10.23.5 Harvest Pharmaceuticals Recent Development
13.24 Merit Pharmaceutical
  10.24.1 Merit Pharmaceutical Company Details
  10.24.2 Merit Pharmaceutical Business Overview and Its Total Revenue
  10.24.3 Merit Pharmaceutical Sympathomimetic Agents Introduction
  10.24.4 Merit Pharmaceutical Revenue in Sympathomimetic Agents Business (2015-2020)
  10.24.5 Merit Pharmaceutical Recent Development
13.25 Tianjin Jinyao Group
  10.25.1 Tianjin Jinyao Group Company Details
  10.25.2 Tianjin Jinyao Group Business Overview and Its Total Revenue
  10.25.3 Tianjin Jinyao Group Sympathomimetic Agents Introduction
  10.25.4 Tianjin Jinyao Group Revenue in Sympathomimetic Agents Business (2015-2020)
  10.25.5 Tianjin Jinyao Group Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Sympathomimetic Agents Key Market Segments
Table 2. Key Players Covered: Ranking by Sympathomimetic Agents Revenue
Table 3. Ranking of Global Top Sympathomimetic Agents Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Sympathomimetic Agents Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Dobutamine
Table 6. Key Players of Dopamine
Table 7. Key Players of Ephedrine
Table 8. Key Players of Epinephrine
Table 9. Key Players of Isoproterenol
Table 10. Key Players of Mephentermine
Table 11. Key Players of Metaraminol
Table 12. Key Players of Methoxamine
Table 13. Key Players of Norepinephrine
Table 14. Key Players of Phenylephrine
Table 15. COVID-19 Impact Global Market: (Four Sympathomimetic Agents Market Size Forecast Scenarios)
Table 16. Opportunities and Trends for Sympathomimetic Agents Players in the COVID-19 Landscape
Table 17. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 18. Key Regions/Countries Measures against Covid-19 Impact
Table 19. Proposal for Sympathomimetic Agents Players to Combat Covid-19 Impact
Table 20. Global Sympathomimetic Agents Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 21. Global Sympathomimetic Agents Market Size by Regions (US$ Million): 2020 VS 2026
Table 22. Global Sympathomimetic Agents Market Size by Regions (2015-2020) (US$ Million)
Table 23. Global Sympathomimetic Agents Market Share by Regions (2015-2020)
Table 24. Global Sympathomimetic Agents Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 25. Global Sympathomimetic Agents Market Share by Regions (2021-2026)
Table 26. Market Top Trends
Table 27. Key Drivers: Impact Analysis
Table 28. Key Challenges
Table 29. Sympathomimetic Agents Market Growth Strategy
Table 30. Main Points Interviewed from Key Sympathomimetic Agents Players
Table 31. Global Sympathomimetic Agents Revenue by Players (2015-2020) (Million US$)
Table 32. Global Sympathomimetic Agents Market Share by Players (2015-2020)
Table 33. Global Top Sympathomimetic Agents Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Sympathomimetic Agents as of 2019)
Table 34. Global Sympathomimetic Agents by Players Market Concentration Ratio (CR5 and HHI)
Table 35. Key Players Headquarters and Area Served
Table 36. Key Players Sympathomimetic Agents Product Solution and Service
Table 37. Date of Enter into Sympathomimetic Agents Market
Table 38. Mergers & Acquisitions, Expansion Plans
Table 39. Global Sympathomimetic Agents Market Size by Type (2015-2020) (Million US$)
Table 40. Global Sympathomimetic Agents Market Size Share by Type (2015-2020)
Table 41. Global Sympathomimetic Agents Revenue Market Share by Type (2021-2026)
Table 42. Global Sympathomimetic Agents Market Size Share by Application (2015-2020)
Table 43. Global Sympathomimetic Agents Market Size by Application (2015-2020) (Million US$)
Table 44. Global Sympathomimetic Agents Market Size Share by Application (2021-2026)
Table 45. North America Key Players Sympathomimetic Agents Revenue (2019-2020) (Million US$)
Table 46. North America Key Players Sympathomimetic Agents Market Share (2019-2020)
Table 47. North America Sympathomimetic Agents Market Size by Type (2015-2020) (Million US$)
Table 48. North America Sympathomimetic Agents Market Share by Type (2015-2020)
Table 49. North America Sympathomimetic Agents Market Size by Application (2015-2020) (Million US$)
Table 50. North America Sympathomimetic Agents Market Share by Application (2015-2020)
Table 51. Europe Key Players Sympathomimetic Agents Revenue (2019-2020) (Million US$)
Table 52. Europe Key Players Sympathomimetic Agents Market Share (2019-2020)
Table 53. Europe Sympathomimetic Agents Market Size by Type (2015-2020) (Million US$)
Table 54. Europe Sympathomimetic Agents Market Share by Type (2015-2020)
Table 55. Europe Sympathomimetic Agents Market Size by Application (2015-2020) (Million US$)
Table 56. Europe Sympathomimetic Agents Market Share by Application (2015-2020)
Table 57. China Key Players Sympathomimetic Agents Revenue (2019-2020) (Million US$)
Table 58. China Key Players Sympathomimetic Agents Market Share (2019-2020)
Table 59. China Sympathomimetic Agents Market Size by Type (2015-2020) (Million US$)
Table 60. China Sympathomimetic Agents Market Share by Type (2015-2020)
Table 61. China Sympathomimetic Agents Market Size by Application (2015-2020) (Million US$)
Table 62. China Sympathomimetic Agents Market Share by Application (2015-2020)
Table 63. Japan Key Players Sympathomimetic Agents Revenue (2019-2020) (Million US$)
Table 64. Japan Key Players Sympathomimetic Agents Market Share (2019-2020)
Table 65. Japan Sympathomimetic Agents Market Size by Type (2015-2020) (Million US$)
Table 66. Japan Sympathomimetic Agents Market Share by Type (2015-2020)
Table 67. Japan Sympathomimetic Agents Market Size by Application (2015-2020) (Million US$)
Table 68. Japan Sympathomimetic Agents Market Share by Application (2015-2020)
Table 69. Southeast Asia Key Players Sympathomimetic Agents Revenue (2019-2020) (Million US$)
Table 70. Southeast Asia Key Players Sympathomimetic Agents Market Share (2019-2020)
Table 71. Southeast Asia Sympathomimetic Agents Market Size by Type (2015-2020) (Million US$)
Table 72. Southeast Asia Sympathomimetic Agents Market Share by Type (2015-2020)
Table 73. Southeast Asia Sympathomimetic Agents Market Size by Application (2015-2020) (Million US$)
Table 74. Southeast Asia Sympathomimetic Agents Market Share by Application (2015-2020)
Table 75. India Key Players Sympathomimetic Agents Revenue (2019-2020) (Million US$)
Table 76. India Key Players Sympathomimetic Agents Market Share (2019-2020)
Table 77. India Sympathomimetic Agents Market Size by Type (2015-2020) (Million US$)
Table 78. India Sympathomimetic Agents Market Share by Type (2015-2020)
Table 79. India Sympathomimetic Agents Market Size by Application (2015-2020) (Million US$)
Table 80. India Sympathomimetic Agents Market Share by Application (2015-2020)
Table 81. Central & South America Key Players Sympathomimetic Agents Revenue (2019-2020) (Million US$)
Table 82. Central & South America Key Players Sympathomimetic Agents Market Share (2019-2020)
Table 83. Central & South America Sympathomimetic Agents Market Size by Type (2015-2020) (Million US$)
Table 84. Central & South America Sympathomimetic Agents Market Share by Type (2015-2020)
Table 85. Central & South America Sympathomimetic Agents Market Size by Application (2015-2020) (Million US$)
Table 86. Central & South America Sympathomimetic Agents Market Share by Application (2015-2020)
Table 87. Pfizer Company Details
Table 88. Pfizer Business Overview
Table 89. Pfizer Product
Table 90. Pfizer Revenue in Sympathomimetic Agents Business (2015-2020) (Million US$)
Table 91. Pfizer Recent Development
Table 92. Sanofi Company Details
Table 93. Sanofi Business Overview
Table 94. Sanofi Product
Table 95. Sanofi Revenue in Sympathomimetic Agents Business (2015-2020) (Million US$)
Table 96. Sanofi Recent Development
Table 97. Novartis Company Details
Table 98. Novartis Business Overview
Table 99. Novartis Product
Table 100. Novartis Revenue in Sympathomimetic Agents Business (2015-2020) (Million US$)
Table 101. Novartis Recent Development
Table 102. Sterimax Company Details
Table 103. Sterimax Business Overview
Table 104. Sterimax Product
Table 105. Sterimax Revenue in Sympathomimetic Agents Business (2015-2020) (Million US$)
Table 106. Sterimax Recent Development
Table 107. Bedford Pharmaceuticals Company Details
Table 108. Bedford Pharmaceuticals Business Overview
Table 109. Bedford Pharmaceuticals Product
Table 110. Bedford Pharmaceuticals Revenue in Sympathomimetic Agents Business (2015-2020) (Million US$)
Table 111. Bedford Pharmaceuticals Recent Development
Table 112. Teva Company Details
Table 113. Teva Business Overview
Table 114. Teva Product
Table 115. Teva Revenue in Sympathomimetic Agents Business (2015-2020) (Million US$)
Table 116. Teva Recent Development
Table 117. Amneal Biosciences Company Details
Table 118. Amneal Biosciences Business Overview
Table 119. Amneal Biosciences Product
Table 120. Amneal Biosciences Revenue in Sympathomimetic Agents Business (2015-2020) (Million US$)
Table 121. Amneal Biosciences Recent Development
Table 122. Baxter Laboratories Business Overview
Table 123. Baxter Laboratories Product
Table 124. Baxter Laboratories Company Details
Table 125. Baxter Laboratories Revenue in Sympathomimetic Agents Business (2015-2020) (Million US$)
Table 126. Baxter Laboratories Recent Development
Table 127. Hikma Pharmaceuticals Company Details
Table 128. Hikma Pharmaceuticals Business Overview
Table 129. Hikma Pharmaceuticals Product
Table 130. Hikma Pharmaceuticals Revenue in Sympathomimetic Agents Business (2015-2020) (Million US$)
Table 131. Hikma Pharmaceuticals Recent Development
Table 132. Amphastar Pharmaceuticals Company Details
Table 133. Amphastar Pharmaceuticals Business Overview
Table 134. Amphastar Pharmaceuticals Product
Table 135. Amphastar Pharmaceuticals Revenue in Sympathomimetic Agents Business (2015-2020) (Million US$)
Table 136. Amphastar Pharmaceuticals Recent Development
Table 137. Marathon Pharmaceuticals Company Details
Table 138. Marathon Pharmaceuticals Business Overview
Table 139. Marathon Pharmaceuticals Product
Table 140. Marathon Pharmaceuticals Revenue in Sympathomimetic Agents Business (2015-2020) (Million US$)
Table 141. Marathon Pharmaceuticals Recent Development
Table 142. Bausch Health Companies Company Details
Table 143. Bausch Health Companies Business Overview
Table 144. Bausch Health Companies Product
Table 145. Bausch Health Companies Revenue in Sympathomimetic Agents Business (2015-2020) (Million US$)
Table 146. Bausch Health Companies Recent Development
Table 147. Sterling-Winthrop Company Details
Table 148. Sterling-Winthrop Business Overview
Table 149. Sterling-Winthrop Product
Table 150. Sterling-Winthrop Revenue in Sympathomimetic Agents Business (2015-2020) (Million US$)
Table 151. Sterling-Winthrop Recent Development
Table 152. Cipla USA Company Details
Table 153. Cipla USA Business Overview
Table 154. Cipla USA Product
Table 155. Cipla USA Revenue in Sympathomimetic Agents Business (2015-2020) (Million US$)
Table 156. Cipla USA Recent Development
Table 157. Nexus Pharmaceuticals Company Details
Table 158. Nexus Pharmaceuticals Business Overview
Table 159. Nexus Pharmaceuticals Product
Table 160. Nexus Pharmaceuticals Revenue in Sympathomimetic Agents Business (2015-2020) (Million US$)
Table 161. Nexus Pharmaceuticals Recent Development
Table 162. Mylan Company Details
Table 163. Mylan Business Overview
Table 164. Mylan Product
Table 165. Mylan Revenue in Sympathomimetic Agents Business (2015-2020) (Million US$)
Table 166. Mylan Recent Development
Table 167. Impax Company Details
Table 168. Impax Business Overview
Table 169. Impax Product
Table 170. Impax Revenue in Sympathomimetic Agents Business (2015-2020) (Million US$)
Table 171. Impax Recent Development
Table 172. ALK Abello Company Details
Table 173. ALK Abello Business Overview
Table 174. ALK Abello Product
Table 175. ALK Abello Revenue in Sympathomimetic Agents Business (2015-2020) (Million US$)
Table 176. ALK Abello Recent Development
Table 177. Lincoln Medical Company Details
Table 178. Lincoln Medical Business Overview
Table 179. Lincoln Medical Product
Table 180. Lincoln Medical Revenue in Sympathomimetic Agents Business (2015-2020) (Million US$)
Table 181. Lincoln Medical Recent Development
Table 182. Amphastar Company Details
Table 183. Amphastar Business Overview
Table 184. Amphastar Product
Table 185. Amphastar Revenue in Sympathomimetic Agents Business (2015-2020) (Million US$)
Table 186. Amphastar Recent Development
Table 187. Emerade Company Details
Table 188. Emerade Business Overview
Table 189. Emerade Product
Table 190. Emerade Revenue in Sympathomimetic Agents Business (2015-2020) (Million US$)
Table 191. Emerade Recent Development
Table 192. Grand Pharma Company Details
Table 193. Grand Pharma Business Overview
Table 194. Grand Pharma Product
Table 195. Grand Pharma Revenue in Sympathomimetic Agents Business (2015-2020) (Million US$)
Table 196. Grand Pharma Recent Development
Table 197. Harvest Pharmaceuticals Company Details
Table 198. Harvest Pharmaceuticals Business Overview
Table 199. Harvest Pharmaceuticals Product
Table 200. Harvest Pharmaceuticals Revenue in Sympathomimetic Agents Business (2015-2020) (Million US$)
Table 201. Harvest Pharmaceuticals Recent Development
Table 202. Merit Pharmaceutical Company Details
Table 203. Merit Pharmaceutical Business Overview
Table 204. Merit Pharmaceutical Product
Table 205. Merit Pharmaceutical Revenue in Sympathomimetic Agents Business (2015-2020) (Million US$)
Table 206. Merit Pharmaceutical Recent Development
Table 207. Tianjin Jinyao Group Company Details
Table 208. Tianjin Jinyao Group Business Overview
Table 209. Tianjin Jinyao Group Product
Table 210. Tianjin Jinyao Group Revenue in Sympathomimetic Agents Business (2015-2020) (Million US$)
Table 211. Tianjin Jinyao Group Recent Development
Table 212. Research Programs/Design for This Report
Table 213. Key Data Information from Secondary Sources
Table 214. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Sympathomimetic Agents Market Share by Type: 2020 VS 2026
Figure 2. Dobutamine Features
Figure 3. Dopamine Features
Figure 4. Ephedrine Features
Figure 5. Epinephrine Features
Figure 6. Isoproterenol Features
Figure 7. Mephentermine Features
Figure 8. Metaraminol Features
Figure 9. Methoxamine Features
Figure 10. Norepinephrine Features
Figure 11. Phenylephrine Features
Figure 12. Global Sympathomimetic Agents Market Share by Application: 2020 VS 2026
Figure 13. Anaphylaxis Case Studies
Figure 14. Cardiac Arrest Case Studies
Figure 15. Others Case Studies
Figure 16. Sympathomimetic Agents Report Years Considered
Figure 17. Global Sympathomimetic Agents Market Size YoY Growth 2015-2026 (US$ Million)
Figure 18. Global Sympathomimetic Agents Market Share by Regions: 2020 VS 2026
Figure 19. Global Sympathomimetic Agents Market Share by Regions (2021-2026)
Figure 20. Porter's Five Forces Analysis
Figure 21. Global Sympathomimetic Agents Market Share by Players in 2019
Figure 22. Global Top Sympathomimetic Agents Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Sympathomimetic Agents as of 2019
Figure 23. The Top 10 and 5 Players Market Share by Sympathomimetic Agents Revenue in 2019
Figure 24. North America Sympathomimetic Agents Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Europe Sympathomimetic Agents Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. China Sympathomimetic Agents Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Japan Sympathomimetic Agents Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Southeast Asia Sympathomimetic Agents Market Size YoY Growth (2015-2020) (Million US$)
Figure 29. India Sympathomimetic Agents Market Size YoY Growth (2015-2020) (Million US$)
Figure 30. Central & South America Sympathomimetic Agents Market Size YoY Growth (2015-2020) (Million US$)
Figure 31. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. Pfizer Revenue Growth Rate in Sympathomimetic Agents Business (2015-2020)
Figure 33. Sanofi Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. Sanofi Revenue Growth Rate in Sympathomimetic Agents Business (2015-2020)
Figure 35. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. Novartis Revenue Growth Rate in Sympathomimetic Agents Business (2015-2020)
Figure 37. Sterimax Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. Sterimax Revenue Growth Rate in Sympathomimetic Agents Business (2015-2020)
Figure 39. Bedford Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. Bedford Pharmaceuticals Revenue Growth Rate in Sympathomimetic Agents Business (2015-2020)
Figure 41. Teva Total Revenue (US$ Million): 2019 Compared with 2018
Figure 42. Teva Revenue Growth Rate in Sympathomimetic Agents Business (2015-2020)
Figure 43. Amneal Biosciences Total Revenue (US$ Million): 2019 Compared with 2018
Figure 44. Amneal Biosciences Revenue Growth Rate in Sympathomimetic Agents Business (2015-2020)
Figure 45. Baxter Laboratories Total Revenue (US$ Million): 2019 Compared with 2018
Figure 46. Baxter Laboratories Revenue Growth Rate in Sympathomimetic Agents Business (2015-2020)
Figure 47. Hikma Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 48. Hikma Pharmaceuticals Revenue Growth Rate in Sympathomimetic Agents Business (2015-2020)
Figure 49. Amphastar Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 50. Amphastar Pharmaceuticals Revenue Growth Rate in Sympathomimetic Agents Business (2015-2020)
Figure 51. Marathon Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Marathon Pharmaceuticals Revenue Growth Rate in Sympathomimetic Agents Business (2015-2020)
Figure 53. Bausch Health Companies Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. Bausch Health Companies Revenue Growth Rate in Sympathomimetic Agents Business (2015-2020)
Figure 55. Sterling-Winthrop Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Sterling-Winthrop Revenue Growth Rate in Sympathomimetic Agents Business (2015-2020)
Figure 57. Cipla USA Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. Cipla USA Revenue Growth Rate in Sympathomimetic Agents Business (2015-2020)
Figure 59. Nexus Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 60. Nexus Pharmaceuticals Revenue Growth Rate in Sympathomimetic Agents Business (2015-2020)
Figure 61. Mylan Total Revenue (US$ Million): 2019 Compared with 2018
Figure 62. Mylan Revenue Growth Rate in Sympathomimetic Agents Business (2015-2020)
Figure 63. Impax Total Revenue (US$ Million): 2019 Compared with 2018
Figure 64. Impax Revenue Growth Rate in Sympathomimetic Agents Business (2015-2020)
Figure 65. ALK Abello Total Revenue (US$ Million): 2019 Compared with 2018
Figure 66. ALK Abello Revenue Growth Rate in Sympathomimetic Agents Business (2015-2020)
Figure 67. Lincoln Medical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 68. Lincoln Medical Revenue Growth Rate in Sympathomimetic Agents Business (2015-2020)
Figure 69. Amphastar Total Revenue (US$ Million): 2019 Compared with 2018
Figure 70. Amphastar Revenue Growth Rate in Sympathomimetic Agents Business (2015-2020)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed